Catalent CEO John Chiminski

Catal­ent inks deal with Phath­om to make GI drug at re­cent­ly-ren­o­vat­ed Ken­tucky site

Sum­mer’s over, but New Jer­sey-based CD­MO Catal­ent had time to squeak in one last deal.

Catal­ent has signed an agree­ment to com­mer­cial­ly

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.